Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rifapentine microspheres
- Development stage
- Unknown
- Lead developer
- Nanjing Chang'ao Pharmaceutical Technology
- Modality
- Small Molecules
- Administration
- Intramuscular
01
Overview
YF-49-92.MLS is a long-acting microsphere formulation of rifapentine, a semi-synthetic rifamycin antibiotic developed by Nanjing Chang'ao Pharmaceutical Technology Co., Ltd. for the treatment of tuberculosis. Rifapentine exerts its antibacterial effect by inhibiting DNA-dependent RNA polymerase in *Mycobacterium tuberculosis*, thereby blocking RNA synthesis and subsequent protein production. The microsphere delivery system (MLS) is designed to provide a sustained-release profile of the drug, which aims to reduce the frequency of administration compared to conventional oral rifapentine regimens. This long-acting injectable approach is intended to improve patient compliance and treatment outcomes in the management of tuberculosis.
- Other names
- rifapentine long-acting microspheres利福喷丁长效微球
02
Targets
RNAP (Bacterial dna-dependent RNA polymerase)
Beyond the preview
Go deeper on rifapentine microspheres.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rifapentine microspheres.